Vlado Perkovic's Publications
About Vlado Perkovic's Publications
Board Member- MBBS,
- PhD,
- FASN,
- FRACP
-
SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
Nephrology Dialysis Transplantation Date published: -
SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
Nephrology Dialysis Transplantation Date published: -
Chronic kidney disease in Asia: Protocol for a collaborative overview
Nephrology Date published: -
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials
Diabetes, Obesity and Metabolism Date published: -
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients
Cochrane Database of Systematic Reviews Date published: -
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy
Diabetes, Obesity and Metabolism Date published: -
A Trial of Extending Hemodialysis Hours and Quality of Life
Journal of the American Society of Nephrology Date published: -
Comparison of exposure response relationship of atrasentan between N orth A merican and A sian populations
Diabetes, Obesity and Metabolism Date published: -
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal ( CANVAS-R ): A randomized, placebo-controlled trial
Diabetes, Obesity and Metabolism Date published: -
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Date published: -
CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk
Date published: -
EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME (R) TRIAL
Date published: -
EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME (R) TRIAL
Date published: -
Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis
American Journal of Kidney Diseases Date published: -
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply
New England Journal of Medicine Date published: -
Review: Revascularization and medical treatment may be similar in atherosclerotic renal artery stenosis
Annals of Internal Medicine Date published:
